Latest Breaking News On - Clinical trial data demonstrating - Page 1 : comparemela.com

100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort . | May 3, 2023

United statesNew zealandBeigene novartisBeigene novartiSuzanne messereIlya rachmanAmerican cancer societyImmix biopharma incExchange commissionTumor shrinkageClinical trial data demonstratingAdvanced metastatic colorectal cancerLowest doseTissue specific therapeuticsFuture marketImmix biopharma